ZymoGenetics buys IL-21 rights; OSI partners with Dako for cancer treatment;

> Novartis profits rose 70 percent to $1.54 billion with an increase in sales from $9.93 billion to $10.08 billion, but its share prices and bottom line could use some help. Report

> The FDA has approved a request by OraSure Technologies for a 12-month shelf life for the company's OraQuick ADVANCE Rapid HIV-1/2 Antibody Test. Report

> ZymoGenetics has just acquired the rights from Novo Nordiskto Interleukin 21 (IL-21), which means that ZymoGenetics will now have worldwide rights to the compound. Release

> OSI Pharmaceuticals and diagnostic company Dako have partnered to develop a new cancer diagnostic test to be a companion product for cancer treatment. Release

>  A single injection of the cholesterol-binding agent CYCLO was enough to rid mice of excessive accumulations of cholesterol in cells, a finding that could point the way to treat the lethal Niemann-Pick type C disease. Report

> Waltham, MA-based Altus Pharmaceuticals is the latest biotech company to fall victim to the economic crisis roiling the industry. Altus announced that it is slashing 107 jobs--75 percent of its work force--and will reduce its research focus to a single program. Report

> Japan's Astellas Pharma is offering a billion dollars in cash for CV Therapeutics. The bid comes in at $16 a share, a whopping 41 percent premium over yesterday's close. And the pharma company, Japan's second largest, says the bid is not contingent on financing. Report

> Basilea Pharmaceutica is adding jobs in Europe and subtracting staffers in the U.S. as the developer positions itself to the conflicting regulatory responses it faces for a key new antibiotic. Report

> Pfizer has been sending some clear signals recently that it fully intends to be an aggressive buyer of biotech assets. But its deal yesterday to pay $68 billion in cash and stock for Wyeth is leaving a host of developers feeling that the takeaway message now is that they're likely to be forgotten. Report

And Finally... A team of researchers at the Pennington Biomedical Research Center in Louisiana have been building a case that a common cold virus can help trigger obesity. Dr. Nikhil Dhurandhar says he has gathered blood samples from a large number of patients at an obesity clinic who appear to be influenced by adenovirus-36. In one of their studies the researchers concluded that the virus is found to be far more common in the obese population than among the slim. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.